Journal article icon

Journal article

Erythroid differentiation enhances RNA mis-splicing in SF3B1-mutant myelodysplastic syndromes with ring sideroblasts

Abstract:

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) commonly develop from hematopoietic stem cells (HSC) bearing mutations in the splicing factor SF3B1 (SF3B1mt). Direct studies into MDS-RS pathobiology have been limited by a lack of model systems that fully recapitulate erythroid biology and RS development and the inability to isolate viable human RS. Here, we combined successful direct RS isolation from patient samples, high-throughput multiomics analysis of cells encompassing the SF3B1mt stem-erythroid continuum, and functional assays to investigate the impact of SF3B1mt on erythropoiesis and RS accumulation. The isolated RS differentiated, egressed into the blood, escaped traditional nonsense-mediated decay (NMD) mechanisms, and leveraged stress-survival pathways that hinder wild-type hematopoiesis through pathogenic GDF15 overexpression. Importantly, RS constituted a contaminant of magnetically enriched CD34+ cells, skewing bulk transcriptomic data. Mis-splicing in SF3B1mt cells was intensified by erythroid differentiation through accelerated RNA splicing and decreased NMD activity, and SF3B1mt led to truncations in several MDS-implicated genes. Finally, RNA mis-splicing induced an uncoupling of RNA and protein expression, leading to critical abnormalities in proapoptotic p53 pathway genes. Overall, this characterization of erythropoiesis in SF3B1mt RS provides a resource for studying MDS-RS and uncovers insights into the unexpectedly active biology of the “dead-end” RS.

Significance: Ring sideroblast isolation combined with state-of-the-art multiomics identifies survival mechanisms underlying SF3B1-mutant erythropoiesis and establishes an active role for erythroid differentiation and ring sideroblasts themselves in SF3B1-mutant myelodysplastic syndrome pathogenesis.

Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1158/0008-5472.CAN-23-3038

Authors

More by this author
Role:
Author
ORCID:
0000-0002-0493-5394
More by this author
Role:
Author
ORCID:
0000-0002-8399-1430
More by this author
Role:
Author
ORCID:
0000-0001-7825-843X
More by this author
Role:
Author
ORCID:
0000-0001-6583-3829
More by this author
Role:
Author
ORCID:
0000-0002-2575-0807


Publisher:
American Association for Cancer Research
Journal:
Cancer Research More from this journal
Volume:
84
Issue:
2
Pages:
211–225
Place of publication:
United States
Publication date:
2023-11-03
Acceptance date:
2023-10-31
DOI:
EISSN:
1538-7445
ISSN:
0008-5472
Pmid:
37921711


Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP